Outpatient CAR T-Cell Therapy as Standard of Care: Current Perspectives and Considerations.

Introduction

Chimeric antigen receptor T-cell therapy (CAR-T) has shown substantial efficacy in the treatment of several types of hematologic malignancies. 1–12 There are now multiple FDA-approved CAR-T products available for commercial use, which has resulted in a persistent and rapid evolution of the treatment paradigm for high-grade non-Hodgkin lymphoma, acute lymphoblastic leukemia, and multiple myeloma. 13–18 Given the growth in the clinical application of these therapies, interest in outpatient administration has also intensified as a mechanism to improve CAR-T accessibility and reduce overall health care resource utilization. Although most initial clinical trials supporting CAR-T use were conducted in the inpatient setting, there is now a growing body of real-world evidence supporting the administration of these products in the ambulatory setting. These studies have demonstrated that CAR-T therapy toxicity is similar to or, in some cases, less frequent or severe than that observed in the registration trials. Although the majority of patients in those studies required an inpatient admission for toxicity management, there remains a subset who can remained in the outpatient setting for the entirety of their treatment course. 19–26 Even among those outpatients who required admission, the median hospital length of stay was approximately 10 days shorter, as compared to patients who received inpatient cell infusion. 22

With the increasing application and usage of CAR-T products comes more familiarity and, as such, substantial improvements in managing their unique toxicities have been made over the past several years. 27–29 Additionally, CAR-T manufacturers are making efforts to engineer products with improved safety profiles. 1 Therefore, it is anticipated that administration of CAR-T therapy will eventually be a standard outpatient procedure. Many centers throughout the USA are currently in the process of establishing outpatient cellular therapy programs to meet this need. There are multiple challenges and factors to consider ( Table 1 ). A successful outpatient program will understand all potential complications of each CAR-T product and be adept at predicting their onset as well as have detailed procedures for prompt recognition and intervention. It will also have the capacity for daily patient monitoring and treatment, a core multidisciplinary team specializing in CAR-T therapy, resources for comprehensive patient education and caregiver support, and the ability to identify or support lodging, so patients can be within the necessary proximity to the treatment center. 19–21,30–33 This review serves to provide a summary of currently published experiences, as well as expert opinion regarding implementation of an outpatient CAR-T therapy program. These principles are generally applicable across all current commercially approved products and associated disease states.

Outpatient CAR-T Therapy Program Implementation

The success of implementing an outpatient CAR-T therapy program necessitates meticulous financial planning and close collaboration with payers, to ensure equitable access, while effectively managing costs. The critical components and considerations involved in establishing and sustaining outpatient CAR-T therapy programs include awareness and planning for FDA and Risk Evaluation and Mitigation Strategies (REMS) requirements, financial considerations, personnel requirements, infrastructure needs, and metrics for program success.

FDA and REMS Considerations

The FDA has approved several CAR-T therapies, each with specific REMS programs to ensure safe administration and management of adverse events. 13–18 While the REMS requirements do not specifically address the site of CAR-T administration, authorized treatment centers must demonstrate an understanding of the requirements, including proximity to the treatment center, patient education, and diligent adverse event monitoring.

Financial Considerations

Outpatient CAR-T therapy programs require diligent financial planning and coordination due to the intricate and costly nature of CAR-T treatments. Establishing a dedicated reimbursement team or enlisting the services of a reimbursement specialist is imperative for navigating the intricacies of CAR-T reimbursement mechanisms and optimizing financial sustainability. This planning encompasses several critical considerations, including reimbursement mechanisms, patient assistance programs, and the allocation of resources in a cost-effective manner. It is imperative to develop a comprehensive budget that accounts for all expenses associated with the administration of outpatient CAR-T therapy. These expenses span from drug acquisition costs and healthcare provider fees to facility charges and ancillary services. Conducting a detailed cost-benefit analysis to evaluate the financial feasibility of transitioning CAR-T therapies to an outpatient setting is equally crucial, and should involve a thorough comparison with inpatient care to ensure long-term financial sustainability. Revenue sources, exploration of potential cost-saving opportunities, and strategies to effectively manage the financial risks associated with outpatient CAR-T therapy programs are vital to programmatic success. Continual monitoring and adaptation of financial strategies remain essential to support the long-term viability of outpatient CAR-T therapy programs.

Key team members should actively engage with payers to negotiate favorable reimbursement terms, while gaining a clear understanding of reimbursement rates, coding procedures, and billing requirements. The American Society for Transplantation and Cellular Therapy (ASTCT) provides a comprehensive billing and coding guide to aid institutions in coding and billing. 34 Notably, Medicare and certain private insurers employ Diagnosis-Related Group (DRG) or Ambulatory Payment Classification (APC) systems for determining reimbursement rates in inpatient and outpatient care settings, respectively. Hospital inpatient reimbursement is calculated using the MS-DRG base payment rate adjusted for hospital geography, diagnosis, case severity and discharge status. 35 APC codes vary based on procedure complexity and cost, making it vital to understand how CAR-T therapy is categorized within these systems. With outpatient administration, Medicare typical reimbursement is based on the hospital outpatient prospective payment system (OPPS). Rigorous adherence to accurate coding and billing practices is essential to maximize reimbursement under the OPPS. Medicaid reimbursement rates are state-dependent and may also be contingent on the specific CAR-T product, patient eligibility, and state regulations. While commercial insurers may cover CAR-T therapy, they often require prior authorization, single case agreements and adherence to specific guidelines. Healthcare institutions must establish close collaboration with insurers to ensure proper reimbursement, especially considering that commercial insurance reimbursement rates can vary, necessitating negotiations on payment terms and prompt claims processing. It is important to prepare for navigating the prior authorization process and handling appeals, when necessary, with a focus on ensuring timely and accurate documentation of medical necessity to facilitate successful appeals. Additionally, the exploration of value-based agreements (VBAs) for CAR-T therapies, which align reimbursement with patient outcomes, could be considered. Value-based agreements encompass shared savings, risk-sharing, or pay-for-performance models, necessitating collaborative negotiations with payers. 36 Some healthcare organizations have also examined bundled payment models, which encompass the entire episode of CAR-T therapy care, from infusion to post-treatment follow-up. 36 Although these models can promote cost containment and care coordination, their successful implementation demands careful financial planning and effective collaboration with payers. Per the European Medicines Agency, CAR-T therapy falls under the designation of Advanced Therapy Medicinal Products (ATMP). 37 In the European Union (EU), decision-making related to pricing and reimbursement is done at a national level and each country must make its own health technology assessment regarding effectiveness, safety, medical necessity, cost-effectiveness and budget impact. 37 Outcome-based reimbursement and spread payment models are being increasingly used in the EU for CAR-T to help increase affordability.

To empower patients in making informed decisions, it is crucial to implement financial counseling services aimed at helping them understand their insurance coverage, copays, and available financial assistance options. Employing financial advocates can further aid patients in navigating the complex reimbursement landscape, identifying potential sources of financial support, and ensuring transparency regarding treatment costs, insurance coverage, and potential financial challenges. Moreover, many CAR-T manufacturers offer patient assistance programs designed to alleviate out-of-pocket costs for eligible patients, encompassing copays, deductibles, and various other expenses, such as local lodging and travel.

Personnel Requirements

The implementation of outpatient CAR-T therapy programs requires the assembly of a highly skilled and specialized multidisciplinary team. This well-structured healthcare team is instrumental in ensuring the safe and effective delivery of patient care as CAR-T therapies transition to the outpatient setting. Key considerations regarding personnel requirements during this pivotal transition encompass:

Physicians: Physicians occupy a central role in patient selection, treatment planning, and ongoing care.

Advanced practice providers (APPs): Under the supervision of physicians, nurse practitioners and physician assistants are instrumental in conducting patient evaluations, contributing to treatment planning, and assisting with regular follow-up care.

Clinical pharmacists: Clinical pharmacists play a pivotal role in medication management, patient education, and adverse event management and are also routinely involved in CAR-T program policy and protocol development. At many institutions, clinical pharmacists also serve as the REMS program authorized representative.

Nurse navigators: Nurse navigators are responsible for orchestrating patient care coordination. They are vital in providing patient education, serving as an accessible point of contact for patients and caregivers throughout the entirety of the CAR-T therapy process.

Cell therapy specialists: These specialists often hold essential certifications and are trained in CAR-T therapy administration and management. Their responsibilities encompass the technical aspects of CAR-T product infusion. Coordinators also ensure the punctual scheduling of patient appointments, follow-up visits, and data collection.

Social workers: Providing indispensable psychosocial support, social workers assist patients and their families in navigating the emotional and practical challenges associated with CAR-T therapy. Their expertise extends to resource navigation, enabling them to connect patients with vital support services.

Financial counselors and patient advocates: Financial counselors are essential as they assist patients in comprehending their insurance coverage, costs, and potential avenues for financial assistance. Simultaneously, patient advocates navigate the healthcare system, addressing non-clinical barriers to care and ensuring patients receive the support they require.

Emergency response team: This specialized team is on standby for critical situations, including severe adverse events. Comprising critical care specialists, intensivists, and rapid response nurses, they are key to ensuring immediate intervention and facilitating patient transfer to a higher level of care, should the need arise.

Data managers and administrative staff: These professionals are entrusted with the collection, organization, and reporting of patient data, which serve critical functions in quality improvement initiatives and research endeavors. They also efficiently handle scheduling, patient communication, medical records, and various administrative tasks that underpin the seamless operation of outpatient CAR-T therapy programs. They may also serve as the REMS program authorized representative for the institution.

Cellular therapy technicians: These personnel are trained in the product chain of custody (collection, storage, handling, preparation, and transport) of CAR-T products and are key to maintaining product quality.

It is paramount to ensure that all personnel receive appropriate training and possess the necessary certifications pertaining to CAR-T therapy, thereby safeguarding patient safety. Effective collaboration among these diverse team members is indispensable for providing comprehensive patient care, vigilant monitoring of adverse events, and the attainment of successful outcomes in the outpatient CAR-T therapy setting. Furthermore, the pursuit of ongoing education and training is imperative to remain current with the latest advancements and best practices within the dynamic field of CAR-T therapy.

Infrastructure Needs

The transition of CAR-T therapies to the outpatient setting necessitates the establishment of specialized infrastructure to facilitate the safe and efficient administration of these cutting-edge treatments.

Designated physical outpatient space: Key considerations include a dedicated treatment area tailored to accommodate CAR-T cell product infusions. This area must strictly adhere to infection control standards while providing comfortable seating arrangements for both patients and their caregivers. The treatment facility should meet all regulatory and accreditation requirements, particularly those concerning the handling of biological materials and patient privacy. Compliance with these standards ensures the utmost safety and quality of care.

In-house laboratory/transfusion services: The availability of an apheresis unit or collaboration with a nearby facility is pivotal for conducting leukapheresis procedures essential for collecting lymphocytes from patients. This unit should boast the requisite apheresis machines, a trained staff, and stringent quality control measures. Additionally, the facility must possess on-site laboratory capabilities to handle the processing, testing, and quality control of CAR-T products. Compliance with Good Manufacturing Practices (GMP) and other regulatory standards for cell processing is non-negotiable to ensure product integrity. Finally, the facility must be able to provide irradiated blood products for CAR-T patients who are pancytopenic.

Ancillary support systems and pathways: The facility should be well-equipped with emergency response tools, including crash carts, defibrillators, and advanced life support equipment. Clearly defined protocols for transferring patients to higher-level care units or facilities in the event of severe adverse events or complications that surpass the outpatient setting’s capacity are essential. Healthcare providers must receive thorough training in rapid response procedures and emergency protocols tailored to CAR-T therapy.

Electronic medical record support: Order sets, lymphodepleting treatment plan and supportive care plan builds, electronic flowsheets for documentation, and safety alerts all provide important patient care safeguards and facilitate standardization of care.

Given the growing availability and importance of remote patient monitoring and virtual services, the integration of telemedicine capabilities is a critical component. This infrastructure should align with regulatory and privacy requirements, facilitating virtual consultations with healthcare providers, particularly for patients residing at a distance from the treatment center.

The transition of CAR-T therapies to the outpatient setting necessitates a holistic approach to infrastructure development that prioritizes patient safety, regulatory adherence, and efficient care delivery. Collaboration with experts in facility planning, infection control, and regulatory affairs is imperative to ensure the establishment and maintenance of a suitable infrastructure tailored to the needs of outpatient CAR-T therapy programs.

Standard Operating Procedures (SOPs)

The seamless transition of CAR-T therapies to an outpatient setting hinges on the development of comprehensive SOPs. These SOPs serve as the bedrock that guarantee safe, efficient, and uniform patient care. They encompass critical facets of CAR-T therapy administration and patient management. Some patients may not be eligible to receive their CAR-T therapy infusions in the outpatient setting. Institutions should establish precise eligibility criteria, including disease indications, performance status, organ function, prior treatments, and caregiver availability. The patient evaluation process should be clearly outlined and incorporate mandated laboratory tests, imaging, and specialist consultations to assess suitability for outpatient CAR-T therapy.

Patient and caregiver understanding and consent regarding treatment procedures, potential adverse events and significance of follow-up appointments are vital to the success of outpatient CAR-T therapy. Therefore, development of SOPs for acquiring informed consent, emphasizing a comprehensive understanding of CAR-T therapy-associated risks, benefits, and expectations is important. Protocols should be standardized but individualized to the patient’s treatment plan.

Stringent procedures governing CAR-T cell product receipt, storage, handling, and preparation, with meticulous adherence to manufacturer-specific requirements, should be established. The preferred regimens, dose modifications, administration guidelines, and supportive care should be clearly defined for the administration of lymphodepletion chemotherapy for each of the CAR-T products. The workflow for CAR-T cell infusion, with comprehensive patient monitoring during and post-administration, accompanied by explicit guidelines for addressing infusion-related adverse events should be described. The appropriate clinical/operational training and competencies for personnel, as well as the responsibilities of involved personnel, should also be clearly outlined in related policies.

Protocols for early recognition, assessment, and management of CAR-T therapy-related adverse events, including CRS and neurologic toxicities, should be defined. A structured schedule and frequency for patient monitoring, involving laboratory evaluations, imaging studies, and clinical assessments should also be established. This includes a comprehensive emergency response plan. Criteria for patient triage and the initiation of rapid response teams in cases of severe adverse events should also be standardized. Guidelines dictating patient discharge criteria, ensuring clinical stability and comprehensive patient/caregiver education regarding post-discharge care should be created to provide seamless communication and transitions of care.

To ensure quality assurance and regulatory compliance, institutions should employ regularly scheduled SOP reviews and updates, with competency assessments for healthcare providers and team members engaged in CAR-T therapy administration and patient care. Centers should confirm alignment of all SOPs with regulatory mandates and guidelines, including FDA-mandated REMS requirements.

SOPs represent indispensable tools for maintaining consistency, safety, and quality in transitioning CAR-T therapy to an outpatient milieu. Periodic SOP reviews and updates are imperative to adapt to evolving practices, ultimately enhancing patient outcomes while upholding the highest standards of patient safety.

Metrics for Program Success

Establishing and monitoring key metrics is of paramount importance during the transition of CAR-T therapies to the outpatient setting. These metrics serve as critical evaluative tools, assessing the program’s effectiveness, patient outcomes, safety protocols, and resource utilization. Below are essential metrics deserving consideration:

Clinical outcomes including overall response rate (and complete response rates), progression-free survival, overall survival, and event-free survival

Adverse events including review of incidence and severity of CRS and neurotoxicity, as well as rates of infection and prolonged cytopenias

Patient experience with the completion of patient satisfaction surveys, patient-reported outcomes, and quality of life assessment

Resource utilization including assessment of infusion center/ambulatory clinic throughput, admission rates for adverse events, length of hospital stay (with associated costs), and frequency of patient ineligibility for CAR-T and/or need for inpatient cell infusion

Financial metrics including the cost per patient incorporating drug expenses, hospitalization and follow-up care, as well as reimbursement rates

Quality improvement metrics, including adherence to standardized protocols, time to CAR-T treatment, and protocol modifications

Patient access and equity metrics including geographic accessibility and monitoring for health disparities

Regularly collecting, dissecting, and acting upon these metrics constitute pivotal steps in optimizing the transition of CAR-T therapies to the outpatient setting. This approach assures patient safety, augments overall care quality, and necessitates the establishment of a data-driven culture. Leveraging electronic health records and data management systems facilitates metric tracking and reporting, contributing to the program’s continuous growth and improvement.

Patient Selection Considerations

Thoughtful patient selection is crucial to maintaining a successful outpatient CAR-T program. Both disease and patient-related factors should be thoroughly evaluated to determine eligibility for outpatient treatment. Table 2 outlines key factors to consider when evaluating a patient for outpatient CAR-T therapy; however, additional criteria may be included based on the individual center’s resources and experience. Patients deemed ineligible for outpatient administration but remaining suitable candidates for CAR-T therapy should receive inpatient CAR-T infusion. These patients may also be considered for re-evaluation for outpatient therapy once the disqualifying issue has been resolved (e.g., resolution of infection or availability of appropriate caregiver) and bridging therapy can be used to control disease during this period. However, waiting to re-evaluate for outpatient administration should not be at the expense of delaying inpatient CAR-T infusion, if it is in the best interest of the patient, given their disease characteristics. Some centers also practice a pre-emptive admission approach for patients who are at higher risk for serious toxicity or adverse outcomes. 26,33 This process involves administering lymphodepleting chemotherapy and CAR-T infusion in the outpatient setting and then admitting the patient either at first sign of grade 1 CRS or immune effector cell-associated neurotoxicity syndrome (ICANS), or at an otherwise pre-determined date, reflective of when toxicities most commonly initially occur.

There are limited data available on outpatient CAR-T infusion in pediatric patients, and most centers still prefer to administer in the inpatient setting. Younger children require the use of alternative toxicity screening tools and increased reliance on their caregivers. However, older children and adolescents may reasonably be considered for outpatient therapy, and the same principles discussed herein would also apply in establishing such a program. Additional considerations may include additional protocols related to patient-specific monitoring and enhanced caregiver assessments and education, as well as the potential need for identification of multiple caregivers.

Daily Outpatient Workflows

Prior to leukapheresis, the patient should receive thorough education of the CAR-T therapy process from the physician and nurse navigator, and be cleared by the various coordinating entities, such as finance and social work. By the start of lymphodepletion in the outpatient setting, a patient should receive counseling from the physician, APP, and/or clinical pharmacist on the chemotherapy, supportive medications, and adverse effects from the procedure. After laboratory and clinical evaluation of the patient, the provider may clear the patient to proceed with lymphodepletion. Tables 3 and 4 provide example daily outpatient workflows and admission pathways for patients undergoing outpatient administration of lymphodepletion and subsequent CAR-T therapy.

Conclusion and Future Directions

The future of CAR-T therapy is outpatient administration; however, the ability to do so requires careful planning to maintain patient safety. It also demands strict program oversight, adaptability, and quality metrics to optimize patient satisfaction and ensure cost-effectiveness. As we gain more real-world experience with outpatient CAR-T administration, it is expected that more community hospitals and hospital-affiliated offsite clinics will also begin providing these therapies. As a consequence, the distance to access a treating facility will be reduced, allowing more patients the opportunity to receive this crucial treatment without the need for temporary relocation. Furthermore, as cell therapy products expand to NK and other cell types, and as manufacturing processes expand to include in house or de-centralized manufacturing, the topic of outpatient delivery will remain pertinent. It is especially imperative that more outpatient programs are established as these products continue to move-up into earlier lines of therapy, as this will only increase the number of patients who need to access them. 3,4,9,12 Additionally, the same infrastructure created for outpatient CAR-T administration has the potential for other applications, such as provision of the newly approved bispecific antibodies, which have a similar toxicity profile to CAR-T therapies. We find ourselves in a new era in the treatment of hematologic malignancies that necessitates adaptability in the ways we provide care to patients. Transitioning CAR-T to the outpatient setting is a critical step in that process.

Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study The Lancet Abramson Jeremy S Palomba M Lia Gordon Leo I Lunning Matthew A Wang Michael Arnason Jon Mehta Amitkumar Purev Enkhtsetseg Maloney David G Andreadis Charalambos Sehgal Alison Solomon Scott R Ghosh Nilanjan Albertson Tina M Garcia Jacob Kostic Ana Mallaney Mary Ogasawara Ken Newhall Kathryn Kim Yeonhee Li Daniel Siddiqi Tanya Elsevier BV London, England 9 2020 396 10254 839 852 0140-6736 10.1016/s0140-6736(20)31366-0 10.1016/s0140-6736(20)31366-0 32888407

Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study The Lancet Berdeja Jesus G Madduri Deepu Usmani Saad Z Jakubowiak Andrzej Agha Mounzer Cohen Adam D Stewart A Keith Hari Parameswaran Htut Myo Lesokhin Alexander Deol Abhinav Munshi Nikhil C O'Donnell Elizabeth Avigan David Singh Indrajeet Zudaire Enrique Yeh Tzu-Min Allred Alicia J Olyslager Yunsi Banerjee Arnob Jackson Carolyn C Goldberg Jenna D Schecter Jordan M Deraedt William Zhuang Sen Hong Infante Jeffrey Geng Dong Wu Xiaoling Carrasco-Alfonso Marlene J Akram Muhammad Hossain Farah Rizvi Syed Fan Frank Lin Yi Martin Thomas Jagannath Sundar Elsevier BV London, England 7 2021 398 10297 314 324 0140-6736 10.1016/s0140-6736(21)00933-8 10.1016/s0140-6736(21)00933-8 34175021

Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial The Lancet Kamdar Manali Solomon Scott R Arnason Jon Johnston Patrick B Glass Bertram Bachanova Veronika Ibrahimi Sami Mielke Stephan Mutsaers Pim Hernandez-Ilizaliturri Francisco Izutsu Koji Morschhauser Franck Lunning Matthew Maloney David G Crotta Alessandro Montheard Sandrine Previtali Alessandro Stepan Lara Ogasawara Ken Mack Timothy Abramson Jeremy S Elsevier BV 6 2022 399 10343 2294 2308 0140-6736 10.1016/s0140-6736(22)00662-6 10.1016/s0140-6736(22)00662-6 35717989

Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma New England Journal of Medicine Locke Frederick L. Miklos David B. Jacobson Caron A. Perales Miguel-Angel Kersten Marie-José Oluwole Olalekan O. Ghobadi Armin Rapoport Aaron P. McGuirk Joseph Pagel John M. Muñoz Javier Farooq Umar van Meerten Tom Reagan Patrick M. Sureda Anna Flinn Ian W. Vandenberghe Peter Song Kevin W. Dickinson Michael Minnema Monique C. Riedell Peter A. Leslie Lori A. Chaganti Sridhar Yang Yin Filosto Simone Shah Jina Schupp Marco To Christina Cheng Paul Gordon Leo I. Westin Jason R. Massachusetts Medical Society 17 2 2022 386 7 640 654 0028-4793 10.1056/nejmoa2116133 10.1056/nejmoa2116133 34891224

Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma New England Journal of Medicine Munshi Nikhil C. Anderson Larry D. Jr. Shah Nina Madduri Deepu Berdeja Jesús Lonial Sagar Raje Noopur Lin Yi Siegel David Oriol Albert Moreau Philippe Yakoub-Agha Ibrahim Delforge Michel Cavo Michele Einsele Hermann Goldschmidt Hartmut Weisel Katja Rambaldi Alessandro Reece Donna Petrocca Fabio Massaro Monica Connarn Jamie N. Kaiser Shari Patel Payal Huang Liping Campbell Timothy B. Hege Kristen San-Miguel Jesús Massachusetts Medical Society 25 2 2021 384 8 705 716 0028-4793 10.1056/nejmoa2024850 10.1056/nejmoa2024850 33626253

5-Year Follow-Up Supports Curative Potential of Axicabtagene Ciloleucel in Refractory Large B-Cell Lymphoma (ZUMA-1) Blood Neelapu Sattva S. Jacobson Caron A. Ghobadi Armin Miklos David B Lekakis Lazaros J. Oluwole Olalekan O. Lin Yi Braunschweig Ira Hill Brian T. Timmerman John M. Deol Abhinav Reagan Patrick M Stiff Patrick Joseph Flinn Ian W. Farooq Umar Goy Andre McSweeney Peter Munoz Javier Siddiqi Tanya Chavez Julio C. Herrera Alex F. Bartlett Nancy L. Bot Adrian A. Shen Rhine R. Dong Jinghui Singh Kanwarjit Miao Harry Kim Jenny J. Zheng Yan Locke Frederick L. American Society of Hematology 23 2 2023 141 19 2307 2315 0006-4971 10.1182/blood.2022018893 10.1182/blood.2022018893 36821768 PMC10646788

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma New England Journal of Medicine Neelapu Sattva S. Locke Frederick L. Bartlett Nancy L. Lekakis Lazaros J. Miklos David B. Jacobson Caron A. Braunschweig Ira Oluwole Olalekan O. Siddiqi Tanya Lin Yi Timmerman John M. Stiff Patrick J. Friedberg Jonathan W. Flinn Ian W. Goy Andre Hill Brian T. Smith Mitchell R. Deol Abhinav Farooq Umar McSweeney Peter Munoz Javier Avivi Irit Castro Januario E. Westin Jason R. Chavez Julio C. Ghobadi Armin Komanduri Krishna V. Levy Ronald Jacobsen Eric D. Witzig Thomas E. Reagan Patrick Bot Adrian Rossi John Navale Lynn Jiang Yizhou Aycock Jeff Elias Meg Chang David Wiezorek Jeff Go William Y. Massachusetts Medical Society 28 12 2017 377 26 2531 2544 0028-4793 10.1056/nejmoa1707447 10.1056/nejmoa1707447 29226797 PMC5882485

Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma New England Journal of Medicine Schuster Stephen J. Bishop Michael R. Tam Constantine S. Waller Edmund K. Borchmann Peter McGuirk Joseph P. Jäger Ulrich Jaglowski Samantha Andreadis Charalambos Westin Jason R. Fleury Isabelle Bachanova Veronika Foley S. Ronan Ho P. Joy Mielke Stephan Magenau John M. Holte Harald Pantano Serafino Pacaud Lida B. Awasthi Rakesh Chu Jufen Anak Özlem Salles Gilles Maziarz Richard T. Massachusetts Medical Society 3 1 2019 380 1 45 56 0028-4793 10.1056/nejmoa1804980 10.1056/nejmoa1804980 30501490

Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study The Lancet Oncology Sehgal Alison Hoda Daanish Riedell Peter A Ghosh Nilanjan Hamadani Mehdi Hildebrandt Gerhard C Godwin John E Reagan Patrick M Wagner-Johnston Nina Essell James Nath Rajneesh Solomon Scott R Champion Rebecca Licitra Edward Fanning Suzanne Gupta Neel Dubowy Ronald D'Andrea Aleco Wang Lei Ogasawara Ken Thorpe Jerill Gordon Leo I Elsevier BV 8 2022 23 8 1066 1077 1470-2045 10.1016/s1470-2045(22)00339-4 10.1016/s1470-2045(22)00339-4 35839786

KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study The Lancet Shah Bijal D Ghobadi Armin Oluwole Olalekan O Logan Aaron C Boissel Nicolas Cassaday Ryan D Leguay Thibaut Bishop Michael R Topp Max S Tzachanis Dimitrios O'Dwyer Kristen M Arellano Martha L Lin Yi Baer Maria R Schiller Gary J Park Jae H Subklewe Marion Abedi Mehrdad Minnema Monique C Wierda William G DeAngelo Daniel J Stiff Patrick Jeyakumar Deepa Feng Chaoling Dong Jinghui Shen Tong Milletti Francesca Rossi John M Vezan Remus Masouleh Behzad Kharabi Houot Roch Elsevier BV London, England 8 2021 398 10299 491 502 0140-6736 10.1016/s0140-6736(21)01222-8 10.1016/s0140-6736(21)01222-8 PMC11613962 34097852

KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma New England Journal of Medicine Wang Michael Munoz Javier Goy Andre Locke Frederick L. Jacobson Caron A. Hill Brian T. Timmerman John M. Holmes Houston Jaglowski Samantha Flinn Ian W. McSweeney Peter A. Miklos David B. Pagel John M. Kersten Marie-Jose Milpied Noel Fung Henry Topp Max S. Houot Roch Beitinjaneh Amer Peng Weimin Zheng Lianqing Rossi John M. Jain Rajul K. Rao Arati V. Reagan Patrick M. Massachusetts Medical Society 2 4 2020 382 14 1331 1342 0028-4793 10.1056/nejmoa1914347 10.1056/nejmoa1914347 32242358 PMC7731441

Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma New England Journal of Medicine San-Miguel Jesús Dhakal Binod Yong Kwee Spencer Andrew Anguille Sébastien Mateos María-Victoria Fernández de Larrea Carlos Martínez-López Joaquín Moreau Philippe Touzeau Cyrille Leleu Xavier Avivi Irit Cavo Michele Ishida Tadao Kim Seok Jin Roeloffzen Wilfried van de Donk Niels W.C.J. Dytfeld Dominik Sidana Surbhi Costa Luciano J. Oriol Albert Popat Rakesh Khan Abdullah M. Cohen Yaël C. Ho P. Joy Griffin James Lendvai Nikoletta Lonardi Carolina Slaughter Ana Schecter Jordan M. Jackson Carolyn C. Connors Kaitlyn Li Katherine Zudaire Enrique Chen Diana Gilbert Jane Yeh Tzu-min Nagle Sarah Florendo Erika Pacaud Lida Patel Nitin Harrison Simon J. Einsele Hermann Massachusetts Medical Society 27 7 2023 389 4 335 347 0028-4793 10.1056/nejmoa2303379 10.1056/nejmoa2303379 37272512

Tisagenlecleucel (Kymriah) [prescribing information] Corp NP East Hanover, NJ 2022

Lisocabtagene maraleucel (Breyanzi) [prescribing information] Juno Therapeutics Bothell, WA 2022

Axicabtagene autoleucel (Yescarta) [prescribing information] Kite Pharma I Santa Monica, CA Santa Monica 2022

Brexucabtagene autoleucel (Tecartus) [prescribing information] Kite Pharma I Santa Monica, CA 2021

Ciltacabtagene autoleucel (Carvykti) [prescribing information] Janssen Biotech I Horsham, PA 2023

Idecabtagene vicleucel (Abecma) [prescribing information] Celgene Corp. aB-MSC Summit, NJ 2021

Outpatient practice utilization for CAR-T and T cell engager in patients with lymphoma and multiple myeloma. Journal of Clinical Oncology Bansal Radhika Paludo Jonas De Menezes Silva Corraes Andre Megan Spychalla Khurana Arushi Hampel Paul Joseph Durani Urshila Dingli David Hayman Suzanne R. Kapoor Prashant Wang Yucai Binder Moritz Kourelis Taxiarchis Kumar Shaji Warsame Rahma M. Bennani Nabila Nora Gertz Morie A. Johnston Patrick B. Ansell Stephen M. Lin Yi American Society of Clinical Oncology (ASCO) 1 6 2023 41 16_suppl 1533 1533 0732-183X 10.1200/jco.2023.41.16_suppl.1533 10.1200/jco.2023.41.16_suppl.1533

Safety and feasibility of outpatient chimeric antigen receptor (CAR) T-cell therapy: experience from a tertiary care center Bone Marrow Transplantation Borogovac Azra Keruakous Amany Bycko Michelle Holter Chakrabarty Jennifer Ibrahimi Sami Khawandanah Mohamad Selby George B. Yuen Carrie Schmidt Sarah Autry Marcus T. Al-Juhaishi Taha Wieduwilt Matthew J. Asch Adam S. Springer Science and Business Media LLC 11 4 2022 57 6 1025 1027 0268-3369 10.1038/s41409-022-01664-z 10.1038/s41409-022-01664-z 35411106 PMC8995917

Feasibility of outpatient administration of axicabtagene ciloleucel and brexucabtagene autoleucel using telemedicine tools: The Vanderbilt experience British Journal of Haematology Dholaria Bhagirathbhai Mehraban Nasima Baer Brittney Long Nancy Jayani Reena V. Byrne Michael T. Kassim Adetola A. Engelhardt Brian G. Savani Bipin N. Oluwole Olalekan O. Wiley 28 6 2022 198 6 1073 1075 0007-1048 10.1111/bjh.18339 10.1111/bjh.18339 35765247

Results from Outreach: A Phase 2 Study of Lisocabtagene Maraleucel (Liso-cel) Administered As Outpatient (Outpt) or Inpatient (Inpt) Treatment in the Community/Nonuniversity Setting in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) Blood Linhares Yuliya Freytes Cesar Cherry Mohamad Bachier Carlos Maris Michael Hoda Daanish Varela Juan Carlos Bellomo Courtney Cross Scott Essell James Fanning Suzanne Terebelo Howard Yimer Habte Courtright Jay Sharman Jeff P. Vedal Min Mailley Connor Espinola Ricardo Mattar Bassam American Society of Hematology 15 11 2022 140 Supplement 1 10416 10418 0006-4971 10.1182/blood-2022-159595 10.1182/blood-2022-159595

Outcomes of Tisagenlecleucel in Lymphoma Patients With Predominant Management in an Ambulatory Setting Clinical Lymphoma Myeloma and Leukemia Nasta Sunita D. Hughes Mitchell E. Namoglu Esin C. Garfall Alfred DiFilippo Heather Ballard Hatcher J. Barta Stefan K. Chong Elise A. Frey Noelle V. Gerson James N. Landsburg Daniel J. Ruella Marco Schuster Stephen J. Svoboda Jakub Weber Elizabeth Porter David L. Elsevier BV 8 2022 22 8 e730 e737 2152-2650 10.1016/j.clml.2022.04.012 10.1016/j.clml.2022.04.012 35595619 PMC10965010

Patient Characteristics and Outcomes of Outpatient Tisagenlecleucel Recipients for B Cell Non-Hodgkin Lymphoma Transplantation and Cellular Therapy Ahmed Nausheen Wesson William Mushtaq Muhammad Umair Porter David L. Nasta Sunita D. Brower Jamie Bachanova Veronika Hu Marie Nastoupil Loretta J. Oluwole Olalekan O. Patel Vivek G. Oliai Caspian Riedell Peter A. Bishop Michael R. Shah Gunjan L. Perales Miguel-Angel Schachter Levanto Maziarz Richard T. McGuirk Joseph P. Elsevier BV 7 2023 29 7 449.e1 449.e7 2666-6367 10.1016/j.jtct.2023.04.019 10.1016/j.jtct.2023.04.019 PMC11027185 37120134

Outpatient CD19-directed CAR T-cell therapy is feasible in patients of all ages British journal of haematology Ly Andrew Sanber Khaled Tsai Hua-Ling Ondo Angela Mooney Kathy Shedeck Audra Baker Julie Imus Philip Hollingsworth Wagner-Johnston Nina Jain Tania Wiley 29 8 2023 203 4 688 692 0007-1048 10.1111/bjh.19090 10.1111/bjh.19090 37642134

Real-World Experience and Optimization of Outpatient Chimeric Antigen Receptor T Cell Therapy Transplantation and Cellular Therapy McGann Mary Davis James A. Gaffney Kelly J. Smith Deidra Edwards Kathy Hess Brian T. Hashmi Hamza Elsevier BV 9 2022 28 9 583 585 2666-6367 10.1016/j.jtct.2022.06.021 10.1016/j.jtct.2022.06.021 35781100

Impact of Preemptive Use of Tocilizumab on Chimeric Antigen Receptor T Cell Outcomes in Non-Hodgkin Lymphoma Transplantation and Cellular Therapy De Philippis Chiara Mannina Daniele Giordano Laura Costantini Elena Marcheselli Simona Mariotti Jacopo Sarina Barbara Taurino Daniela Santoro Armando Bramanti Stefania Elsevier BV 7 2023 29 7 429.e1 429.e6 2666-6367 10.1016/j.jtct.2023.03.019 10.1016/j.jtct.2023.03.019 36966874

How I Treat Refractory CRS and ICANS Following CAR T-cell Therapy Blood Jain Michael D. Smith Melody Shah Nirali N American Society of Hematology 29 3 2023 141 20 2430 2442 0006-4971 10.1182/blood.2022017414 10.1182/blood.2022017414 36989488 PMC10329191

Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B-cell lymphoma British Journal of Haematology Oluwole Olalekan O. Bouabdallah Krimo Muñoz Javier De Guibert Sophie Vose Julie M. Bartlett Nancy L. Lin Yi Deol Abhinav McSweeney Peter A. Goy Andre H. Kersten Marie José Jacobson Caron A. Farooq Umar Minnema Monique C. Thieblemont Catherine Timmerman John M. Stiff Patrick Avivi Irit Tzachanis Dimitrios Kim Jenny J. Bashir Zahid McLeroy Jeff Zheng Yan Rossi John M. Johnson Lisa Goyal Lovely van Meerten Tom Wiley 22 7 2021 194 4 690 700 0007-1048 10.1111/bjh.17527 10.1111/bjh.17527 34296427 PMC8457222

Educating Multidisciplinary Care Teams, Patients, and Caregivers on CAR T-Cell Therapy Journal of the Advanced Practitioner in Oncology Beaupierre Alix Kahle Nicole Lundberg Rachel Patterson Amy Harborside Press, LLC 1 5 2019 10 4 29 40 2150-0878 10.6004/jadpro.2019.10.4.12 10.6004/jadpro.2019.10.4.12 33520344 PMC7521122

Chimeric antigen receptor T-cell therapy: Challenges and framework of outpatient administration eJHaem Gatwood Katie S. Dholaria Bhagirathbhai R. Lucena Mariana Baer Brittney Savani Bipin N. Oluwole Olalekan O. Wiley 19 11 2021 3 S1 54 60 2688-6146 10.1002/jha2.333 10.1002/jha2.333 35844300 PMC9176074

Chimeric Antigen Receptor T Cell Therapy: A Comprehensive Review of Clinical Efficacy, Toxicity, and Best Practices for Outpatient Administration Transplantation and Cellular Therapy Alexander Maurice Culos Kathryn Roddy Julianna Shaw J. Ryan Bachmeier Christina Shigle Terri Lynn Mahmoudjafari Zahra Elsevier BV 7 2021 27 7 558 570 2666-6367 10.1016/j.jtct.2021.01.014 10.1016/j.jtct.2021.01.014 33910041

Perspectives on outpatient administration of CAR-T cell therapy in aggressive B-cell lymphoma and acute lymphoblastic leukemia Journal for ImmunoTherapy of Cancer Myers G Doug Verneris Michael R Goy Andre Maziarz Richard T BMJ 4 2021 9 4 e002056 2051-1426 10.1136/jitc-2020-002056 10.1136/jitc-2020-002056 33846220 PMC8047987

CAR-T Therapy Coding and Billing Guide Therapy ASfTaC 2023 https://www.astct.org/Portals/0/Docs/Practice/ASTCT_1147740-23_BillingandCodingUpdates_Q2_FINAL.pdf?ver=BQMSA9e0IOXv5BPaXkGsBA%3d%3d

CAR-T Reimbursement Updated in FY 2024 IPPS Final Rule Avalere Kolton G. 2023 https://avalere.com/insights/car-t-reimbursement-updated-in-ipps-final-rule

Payment methods for healthcare providers working in outpatient healthcare settings Cochrane Database of Systematic Reviews Jia Liying Meng Qingyue Scott Anthony Yuan Beibei Zhang Lu Wiley 20 1 2021 1 1 1465-1858 10.1002/14651858.cd011865.pub2 10.1002/14651858.cd011865.pub2 33469932 PMC8094987

CAR-T State of the Art and Future Challenges, A Regulatory Perspective International Journal of Molecular Sciences Giorgioni Lorenzo Ambrosone Alessandra Cometa Maria Francesca Salvati Anna Laura Magrelli Armando MDPI AG 22 7 2023 24 14 11803 1422-0067 10.3390/ijms241411803 10.3390/ijms241411803 37511562 PMC10380644